Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Abstract Text:

Kiminori Uka,Hiroshi Aikata,Shintaro Takaki,Daiki Miki,Tomokazu Kawaoka,Soo Cheol Jeong,Shoichi Takahashi,Naoyuki Toyota,Katsuhide Ito,Kazuaki Chayama,Kiminori Uka,Hiroshi Aikata,Shintaro Takaki,Daiki Miki,Tomokazu Kawaoka,Soo Cheol Jeong,Shoichi Takahashi,Naoyuki Toyota,Katsuhide Ito,Kazuaki Chayama,

BACKGROUND: Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We investigated the pretreatment predictive factors of early response, time to progression (TTP), and survival in response to intraarterial 5-FU/IFN combination therapy. METHODS: Patients with nonresectable HCC and variable PVTT grades (without PVTT to PVTT in the trunk) received intraarterial 5-FU/IFN combination therapy (n = 55). RESULTS: After two courses of the combination therapy, 1 (2%), 15 (27%), 16 (29%), 12 (22%), and 11 (20%) of 55 patients showed complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or had dropped out (DO), respectively, when their early response to treatment was assessed. Univariate analysis identified only hepatitis C virus (HCV) antibody positivity as having significantly influenced the early response (P = 0.028) and TTP (P = 0.021). Multivariate analysis identified performance status (P = 0.003) and HCV antibody positivity (P = 0.007) as significant and independent determinants of survival. PVTT grade did not influence early response, TTP, or survival. The survival rate was significantly higher in patients who achieved CR or PR than in those that assessed as SD or PD, or DO (P < 0.0001, each). CONCLUSIONS: HCV antibody positivity may be a significant pretreatment predictor of early response, TTP, and survival of patients with advanced HCC treated with 5-FU/IFN. CR or PR as the early response to the combination therapy might indicate a more favorable prognosis in patients with advanced HCC. PVTT grade did not seem to influence the efficacy of combination therapy.

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Publishing Authors By Initials

K Uka,H Aikata,S Takaki,D Miki,T Kawaoka,SC Jeong,S Takahashi,N Toyota,K Ito,K Chayama,K Uka,H Aikata,S Takaki,D Miki,T Kawaoka,SC Jeong,S Takahashi,N Toyota,K Ito,K Chayama,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of gastroenterology

VOLUME: 42

Page Numbers: 845-53

Journal Abbreviation: J. Gastroenterol.

ISSN: 0944-1174

DAY: 15

MONTH: 10

YEAR: 2007

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9430794

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.

AFFILIATION: Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734-8551, Japan.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma Related Publications

• A case of multiple hepatic peribiliary cysts which contributed to the obstructive jaundice and led to liver failure at the young man with von Recklinghausen's disease.
• A case report of anaphylactoid purpura with acute abdominal pain secondary to trauma caused by traffic accident.
• Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.
• Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage.
• Clinical significance of type V(I) pit pattern subclassification in determining the depth of invasion of colorectal neoplasms.
• Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
• Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma.
• Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-alpha and Ribavirin. A Prospective Randomized Controlled Trial.
• Evaluation of Gastric Cancer Risk Using Topography of Histological Gastritis: A Large-scaled Cross-sectional Study.
• Evaluation of colon cancer vascularity by flash echo imaging.
• Evaluation of microvessels in colorectal tumors by narrow band imaging magnification.
• Genetic polymorphisms and head and neck cancer risk (Review).
• Helicobacter pylori-associated gastritis is related to babA2 expression without heterogeneity of the 3' region of the cagA genotype in gastric biopsy specimens.
• Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer.
• Long-term Ultrasonographic Follow-up Study of Gastric Motility in Patients with Functional Dyspepsia.
• Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
• Predicting the need for surgery in Crohn's disease with contrast harmonic ultrasound.
• Predictors and long-term prognostic implications of angiographic slow/no-flow during percutaneous coronary intervention for acute myocardial infarction.
• Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
• Primary follicular lymphoma of the gastrointestinal tract: a retrospective case series.
• Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
• Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study.
• Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia.
• Selective decrease in colonic CD56(+) T and CD161(+) T cells in the inflamed mucosa of patients with ulcerative colitis.
• Serum pepsinogen levels in the Japanese population: prospective study of 9 years of follow-up.
• Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
• Strategy for treatment of nonerosive reflux disease in Asia.
• Successful treatment of an entecavir-resistant hepatitis B virus variant.
• Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases.
• The number of criminal prosecutions against physicians due to medical negligence is on the rise in Japan.